


Driving More Affordable, Accessible and Effective Care

Larry Merlo

President & Chief Executive Officer





Forward-looking Statements; Non-GAAP Measures

During today's presentation, we will make forward-looking statements within the meaning of the federal securities laws. By their nature, all forward-looking statements involve risks and uncertainties. Actual results may differ materially from those contemplated by the forward-looking statements for a number of reasons as described in our SEC filings, including the risk factors section and cautionary statement disclosure in those filings.

During this presentation, we will also use some non-GAAP financial measures when talking about our company's performance, including free cash flow, cash available to enhance shareholder value and Adjusted EPS. In accordance with SEC regulations, you can find the definitions of these non-GAAP items, as well as reconciliations to comparable GAAP measures, on the investor relations portion of our website.

Key Accomplishments in 2016

✓ Strong financial performance

Adjusted EPS growth of ~12%;
Free Cash Flow of \$6.9B



✓ Enhanced Long-Term Care

Introduced pilot programs to improve
patient care



✓ Successful PBM selling season

\$7.8B gross new business for 2017;
client retention of ~97%



✓ Completed Target integration

Integrated Target pharmacies and clinics



✓ Effectively managed trend

Achieved client drug trend of only 3.3%
through September



✓ Advanced front store strategies

Delivered profitable sales through
enhanced offerings, personalization
and digital capabilities



✓ Superior Specialty growth

Dispensed revenue growth of ~19%,
continuing to outpace market



✓ Plan to reaccelerate growth

Includes new partnerships with payors,
new PBM products, cost savings initiative
and capital deployment





Driving More Affordable, Accessible and Effective Care


Affordable



Accessible



Effective





Driving More Affordable, Accessible and Effective Care

Affordable

Cost management solutions to drive real savings in the health care economy

Accessible

Unmatched breadth of assets to connect with patients fully across the care continuum

Effective

Analytics capabilities and clinical programs to help drive adherence and health outcomes



Today's Key Takeaways

Driving More Affordable, Accessible and Effective Care

Driving Outcomes and Savings

In an era of rising costs, we are the optimal partner to deliver savings and help improve outcomes for health care stakeholders

Providing the Front Door and the Last Mile

Pharmacy has the highest frequency of interaction and our unmatched patient touch points across the enterprise help shape behavior

Best Partner for PBMs and Health Plans

We can partner with all PBMs and health plans, leveraging our enterprise assets and capabilities to meet their individual needs

Integrated Pharmacy Care

Our exclusive programs are seamlessly integrated through our Health Engagement Engine, providing better member experience and results

Positioned for L-T Enterprise Growth

Maximize shareholder value with an enterprise mindset; generate strong cash flow and employ a disciplined approach to capital allocation



Today's Agenda

Topic		Speaker
	Maximizing Shareholder Value With an Enterprise Mindset	Dave Denton
	Delivering Value for All Health Care Stakeholders	Larry Merlo
	Meeting the Health Care Challenges of Tomorrow	Jon Roberts
	Leading the Evolution of the Specialty Model	Alan Lotvin
	Capitalizing on the <i>Retailization</i> of Health Care	Helena Foulkes



Endnotes

Slide 3

1. Refer to non-GAAP tab in Analyst Day presentation book or the Investor Relations portion of the CVS Health website for Adjusted EPS reconciliation for the year ending December 31, 2016 and the year ended December 31, 2015.
2. Refer to non-GAAP tab in Analyst Day presentation book or the Investor Relations portion of the CVS Health website for Free Cash Flow reconciliation for the year ending December 31, 2016 and the year ended December 31, 2015.
3. Adjusted EPS growth and Free Cash Flow are based on midpoints of 2016 guidance.
4. Gross new business revenue excludes Medicare Part D SilverScript individual products.
5. Client retention rate is defined as: 1 less (projected 2017 lost revenues from any known terminations plus annualization of any mid-year 2016 terminations, divided by estimated 2017 PBM revenues) expressed as a percentage. Both terminations and PBM revenues exclude Medicare Part D SilverScript individual products.
6. Client drug trend is the measure of growth in prescription spending per member per month. Trend calculations take into account the effects of drug price, drug utilization and the mix of branded versus generic drugs. Trend figures cited are for commercial cohort (health plans and employers). Trend is 2016 YTD through September and is reported net of rebates.
7. Specialty growth defined as 2016 forecasted dispensed revenue growth for specialty products vs. 2015.